|
|
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 22:33
|
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire EN)
|
|
|
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 4:00 PM ET....
|
|
|
03.06.26 - 22:33
|
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting (GlobeNewswire EN)
|
|
|
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 17, 2026, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET....
|
|
|
|
|
|
|
|
|
|
|
03.06.26 - 21:42
|
Corporate News: Amgen (EQS)
|
|
|
EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|